BEA-28 / Beactica - LARVOL DELTA

Beactica Therapeutics selects BEA-28 as a preclinical candidate, a first-in-class TEAD degrader for biomarker-selected cancers (PRNewswire) - "In preclinical studies, BEA-28 showed robust tumour regressions at well-tolerated doses, and restored sensitivity to KRAS inhibitors in resistant models. The programme advances a biomarker-led, combination strategy, with a high unmet need cancer as the lead indication....BEA-28 was selected after meeting predefined success criteria covering chemistry, in vitro and in vivo pharmacology, ADME and pharmacokinetic properties. The molecule will now advance into comprehensive candidate validation, including non-regulatory (pre-GLP) toxicology, scale-up chemistry, and advanced formulation profiling. Studies formally supporting IND-enabling requirements will be initiated following candidate drug nomination."

New molecule • Preclinical • Oncology